| 复发转移胃肠间质瘤的治疗对策 |
| |
| 引用本文： | 梁寒.复发转移胃肠间质瘤的治疗对策[J].中华胃肠外科杂志,2014(4):309-311. |
| |
| 作者姓名： | 梁寒 |
| |
| 作者单位： | 天津医科大学肿瘤医院胃部肿瘤科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室, 300060 |
| |
| 摘 要： | 靶向药物是治疗复发转移胃肠间质瘤（GIST）的首选。酪氨酸激酶抑制剂（TKI）伊马替尼耐药后，特别是外显子9突变者接受舒尼替尼治疗可以获得满意的疾病控制率。TKI联合手术切除可能延长GIST肝转移患者的生存期。在严格掌握适应证的前提下，TKI联合手术可能是目前治疗复发转移GIST的最佳模式。多激酶抑制剂regorafenib和帕唑帕尼（pazopanib）对标准治疗失败的GIST患者仍可获得显著疗效。
|
| 关 键 词： | 胃肠间质瘤 复发 转移 治疗对策 |
Treatment strategy for recurrent and metastatic gastrointestinal stromal tumors |
| |
| Institution: | Liang Hart. Department of Gastrointestinal Surgery, Tianjin Cancer Hospital, Tianjin Medical University, Tianjin 300060, China |
| |
| Abstract: | Targeted therapy is the first line treatment for patients with recurrent/metastatic gastrointestinal stromal tumors （GIST）. Sunitinib is effective for patients who have failed imatinib, specially with c-kit exon 9 gene mutation. Tyrosine kinase inhibitors combined with partial hepatectomy may increase the overall survival of GIST patients with liver metastasis. Selective patients with recurrent or metastatic GIST benefit from surgical resection. Regor, ffenib and pazopanib can provide a significant improvement in progression-free survival in patients after failure of standard treatment. |
| |
| Keywords: | Gastrointestinal stromal tumors Recurrence Metastasis Treatment strategy |
| 本文献已被 维普 等数据库收录！ |
